Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Revision History For: SangStat Med. (SANG) - 10 of 10 analysts say Strong Buy

No earlier versions found for this Subject.

Return to SangStat Med. (SANG) - 10 of 10 analysts say Strong Buy

I recently purchased some of this stock, and have been amazed at the paucity of online talk about it (... maybe a good sign!). A check of Zacks will show that out of 10 broker/analysts covering it, All Ten give it a Strong Buy rating, making it #1 in their rankings out of the 115 stocks in their "Med-Biomed/Gene industry sector -- see
ultra.zacks.com

To get the ball rolling, I will post some of the data I've collected that's not copyright-protected, & maybe someone will join me in tracking the coming success of this company.

Sangstat Medical Corporation offers a broad spectrum of therapeutic and monitoring product candidates to improve the outcome of organ transplants. Of SangStat's 11 products and product candidates, one is a licensed-in, commercially proven drug, 3 are currently available for clinical or research use, and several others are at an advanced stage of development. The company's products include CELSIOR, which preserves organ viability prior to transplantation; sHLA-STAT Class I, which improves the early non-invasive diagnosis of acute rejection episodes; and THYMOGLOBULIN, a commercially-proven drug to treat acute graft rejection episodes and prevent graft loss.